MCID: ADN018
MIFTS: 60

Adenoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Adenoma

MalaCards integrated aliases for Adenoma:

Name: Adenoma 12 75 55 15 72
Acinar Cell Adenoma 12 72
Adenomas 12 15
Acinic Cell Adenoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:657
MeSH 44 D000236
NCIt 50 C2855 C4196
SNOMED-CT 68 32048006 79041005
UMLS 72 C0001430 C0334389

Summaries for Adenoma

Disease Ontology : 12 A cell type benign neoplasm that is composed of epithelial tissue in which tumor cells form glands or glandlike structures.

MalaCards based summary : Adenoma, also known as acinar cell adenoma, is related to pituitary adenoma, prolactin-secreting and growth hormone secreting pituitary adenoma. An important gene associated with Adenoma is PLAG1 (PLAG1 Zinc Finger), and among its related pathways/superpathways are Signaling by GPCR and PI3K-Akt signaling pathway. The drugs Linaclotide and Scopolamine have been mentioned in the context of this disorder. Affiliated tissues include pituitary, thyroid and colon, and related phenotypes are Decreased viability in esophageal squamous lineage and Downregulation of NFkappaB pathway

Wikipedia : 75 An adenoma is a benign tumor of epithelial tissue with glandular origin, glandular characteristics, or... more...

Related Diseases for Adenoma

Diseases related to Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1739)
# Related Disease Score Top Affiliating Genes
1 pituitary adenoma, prolactin-secreting 34.9 PRL MEN1 GNAS AIP
2 growth hormone secreting pituitary adenoma 34.6 PRL GNAS AIP
3 sebaceous adenoma 34.6 MSH2 MLH1
4 parathyroid adenoma 34.5 RET MEN1 CDC73 CCND1
5 colorectal adenoma 34.5 MSH2 MLH1 KRAS CTNNB1 APC
6 silent pituitary adenoma 34.5 MEN1 AIP
7 null pituitary adenoma 34.3 MEN1 AIP
8 periampullary adenoma 34.3 KRAS APC
9 acromegaly 34.1 PRL MEN1 GNAS AIP
10 polyposis syndrome, hereditary mixed, 1 34.0 MLH1 APC
11 mutyh-associated polyposis 33.8 SMAD4 KRAS APC
12 hyperparathyroidism 1 33.8 MEN1 CDC73
13 carney complex variant 33.7 MEN1 GNAS AIP
14 hyperparathyroidism 2 with jaw tumors 33.6 RET MEN1 CDC73 CCND1
15 familial adenomatous polyposis 1 33.5 CTNNB1 APC
16 hyperthyroidism 33.3 TSHR PRL GNAS
17 endometrial adenocarcinoma 33.1 MLH1 KRAS CTNNB1
18 mismatch repair cancer syndrome 33.1 MSH2 MLH1 CTNNB1 APC
19 parathyroid carcinoma 33.0 RET MEN1 CDC73 CCND1
20 familial isolated hyperparathyroidism 32.9 RET MEN1 CDC73
21 multiple endocrine neoplasia, type iia 32.8 RET MEN1 CDC73
22 primary hyperparathyroidism 32.8 RET PRL MEN1 CDC73 CCND1
23 multiple endocrine neoplasia, type i 32.8 RET PRL MEN1 GNAS CDC73
24 familial adenomatous polyposis 32.6 SMAD4 MSH2 MLH1 KRAS CTNNB1 CCND1
25 hyperparathyroidism 32.5 RET MEN1 CDC73
26 pituitary tumors 32.5 PRL MEN1 GNAS AIP
27 colorectal cancer 31.7 TGFBR2 SMAD4 RET MSH2 MLH1 KRAS
28 hormone producing pituitary cancer 31.6 MEN1 GNAS AIP
29 gastric cancer 31.4 TGFBR2 SMAD4 MSH2 MLH1 KRAS CTNNB1
30 mccune-albright syndrome 31.4 PRL GNAS APC
31 hypothyroidism 31.4 TSHR RET PRL GNAS
32 pituitary gland disease 31.4 PRL MEN1 AIP
33 peutz-jeghers syndrome 31.4 SMAD4 CTNNB1 APC
34 colorectal adenocarcinoma 31.3 MSH2 MLH1 KRAS CTNNB1
35 fibrous dysplasia 31.3 PRL GNAS APC
36 colon adenocarcinoma 31.2 MLH1 KRAS CTNNB1 APC
37 hyperplastic polyposis syndrome 31.0 KRAS APC
38 thyroid gland disease 31.0 TSHR RET PRL
39 cholangiocarcinoma 30.9 SMAD4 KRAS CTNNB1 CCND1
40 attenuated familial adenomatous polyposis 30.9 MSH2 APC
41 von hippel-lindau syndrome 30.9 RET MEN1 CCND1
42 differentiated thyroid carcinoma 30.8 TSHR RET KRAS
43 hepatoblastoma 30.7 PLAG1 CTNNB1 APC
44 urachal adenocarcinoma 30.7 KRAS GNAS
45 bladder urothelial carcinoma 30.7 MLH1 KRAS CTNNB1 CCND1
46 parathyroid gland disease 30.6 RET MEN1 CDC73
47 multiple endocrine neoplasia, type iv 30.6 RET PRL MEN1 AIP
48 thyroid carcinoma, familial medullary 30.5 RET MEN1 KRAS
49 adenocarcinoma 30.5 TGFBR2 SMAD4 RET MLH1 KRAS GNAS
50 testotoxicosis 30.5 LHCGR GNAS

Graphical network of the top 20 diseases related to Adenoma:



Diseases related to Adenoma

Symptoms & Phenotypes for Adenoma

GenomeRNAi Phenotypes related to Adenoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.93 APC CCND1 CTNNB1 GNAS KRAS MEN1
2 Downregulation of NFkappaB pathway GR00313-A 9.13 APC MEN1 SMAD4
3 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.1 APC GNAS MSH2 PLAGL2 SMAD4 TGFBR2

MGI Mouse Phenotypes related to Adenoma:

46 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.51 AIP APC CCND1 CDC73 CTNNB1 GNAS
2 endocrine/exocrine gland MP:0005379 10.51 AIP APC CCND1 CDC73 CTNNB1 GNAS
3 homeostasis/metabolism MP:0005376 10.5 AIP APC CCND1 CDC73 CTNNB1 GNAS
4 growth/size/body region MP:0005378 10.47 AIP APC CCND1 CDC73 CTNNB1 GNAS
5 digestive/alimentary MP:0005381 10.44 APC CCND1 CDC73 CTNNB1 KRAS LHCGR
6 immune system MP:0005387 10.41 APC CCND1 CDC73 CTNNB1 GNAS KRAS
7 behavior/neurological MP:0005386 10.4 APC CCND1 CDC73 CTNNB1 GNAS KRAS
8 cardiovascular system MP:0005385 10.39 AIP APC CCND1 CDC73 CTNNB1 GNAS
9 mortality/aging MP:0010768 10.38 AIP APC CCND1 CDC73 CTNNB1 GNAS
10 hematopoietic system MP:0005397 10.37 APC CCND1 CDC73 CTNNB1 GNAS KRAS
11 neoplasm MP:0002006 10.31 AIP APC CCND1 CDC73 CTNNB1 GNAS
12 embryo MP:0005380 10.28 AIP APC CDC73 CTNNB1 KRAS MEN1
13 integument MP:0010771 10.26 AIP APC CCND1 CDC73 CTNNB1 GNAS
14 craniofacial MP:0005382 10.25 APC CCND1 CDC73 CTNNB1 GNAS KRAS
15 nervous system MP:0003631 10.25 APC CCND1 CDC73 CTNNB1 GNAS KRAS
16 liver/biliary system MP:0005370 10.24 AIP APC CDC73 CTNNB1 GNAS KRAS
17 muscle MP:0005369 10.11 APC CDC73 CTNNB1 GNAS KRAS MEN1
18 reproductive system MP:0005389 10.07 APC CCND1 CDC73 CTNNB1 KRAS LHCGR
19 limbs/digits/tail MP:0005371 10.05 APC CTNNB1 GNAS KRAS RET SMAD4
20 normal MP:0002873 9.97 APC CCND1 CTNNB1 GNAS KRAS RET
21 renal/urinary system MP:0005367 9.92 APC CDC73 CTNNB1 GNAS KRAS LHCGR
22 respiratory system MP:0005388 9.81 CCND1 CDC73 CTNNB1 GNAS KRAS LHCGR
23 skeleton MP:0005390 9.61 APC CCND1 CDC73 CTNNB1 GNAS KRAS
24 vision/eye MP:0005391 9.23 APC CCND1 CTNNB1 KRAS MLH1 PLAG1

Drugs & Therapeutics for Adenoma

Drugs for Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 484)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Linaclotide Approved Phase 4 851199-59-2 65351
2
Scopolamine Approved, Investigational Phase 4 6533-68-2, 51-34-3 5184
3
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 441411 12560
4
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
5
Clarithromycin Approved Phase 4 81103-11-9 84029
6
Pantoprazole Approved Phase 4 102625-70-7 4679
7
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
8
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
9
Prucalopride Approved Phase 4 179474-81-8
10
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
11
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
12
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
13
Metronidazole Approved Phase 4 443-48-1 4173
14
Pasireotide Approved Phase 4 396091-73-9 9941444
15
Metformin Approved Phase 4 657-24-9 4091 14219
16
Methylene blue Approved, Investigational Phase 4 61-73-4
17
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
18
Magnesium citrate Approved Phase 4 3344-18-1
19
Sodium citrate Approved, Investigational Phase 4 68-04-2
20
Glucagon Approved Phase 4 16941-32-5
21
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
22
Liraglutide Approved Phase 4 204656-20-2 44147092
23
Zinc Approved, Investigational Phase 4 7440-66-6 32051
24
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
25
Cefdinir Approved Phase 4 91832-40-5 6915944
26
Sulfamethoxazole Approved Phase 4 723-46-6 5329
27
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
28
Cefazolin Approved Phase 4 25953-19-9 656510 33255
29
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
30
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
31
Acetaminophen Approved Phase 4 103-90-2 1983
32
Codeine Approved, Illicit Phase 4 76-57-3 5284371
33
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
34
Nitric Oxide Approved Phase 4 10102-43-9 145068
35
Sodium sulfate Approved, Vet_approved Phase 4 7757-82-6
36
Dyclonine Approved Phase 4 586-60-7 3180
37
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
38
lanreotide Approved Phase 4 108736-35-2
39
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
40
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 54670067 5785
41
Ecabet Investigational Phase 4 33159-27-2, 86408-72-2 65781
42
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
43 Cholinergic Agents Phase 4
44 Muscarinic Antagonists Phase 4
45 Cholinergic Antagonists Phase 4
46 Bromides Phase 4
47 Butylscopolammonium Bromide Phase 4
48 Erythromycin stearate Phase 4
49 Erythromycin Estolate Phase 4
50 Erythromycin Ethylsuccinate Phase 4

Interventional clinical trials:

(show top 50) (show all 1025)
# Name Status NCT ID Phase Drugs
1 Does Hyoscine N-butylbromide Administered During Colonoscopy Increase the Polyp Detection Rate? a Randomized, Single Center, Double Blind, Placebo-controlled Study Unknown status NCT01609855 Phase 4 Hyoscine Butyl Bromide 20mg/2 ml i.v.;Saline 2 ml i.v.
2 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-protocol is Identical to Study No. 0519-10-TLV- Minors' Adjusted Version Unknown status NCT02354560 Phase 4 Erythromycin
3 Erythromycin as a Novel Therapy Against Familial Adenomatous Polyposis and Sporadic Colorectal Cancer by APC Nonsense Mutation Readthrough. Unknown status NCT02175914 Phase 4 Erythromycin
4 Efficacy and Cost-effectiveness of Colonoscopy vs. Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia (eCOLO-FITS): A Randomized Multicenter Trial Unknown status NCT01767870 Phase 4
5 Effects of Ilaprazole 20mg on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone Endoscopic Submucosal Dissection(ESD) for Gastric Adenoma or Early Gastric Cancer. Unknown status NCT02638584 Phase 4 Ilaprazole;Rabeprazole
6 Impact of Reinforced Education by Wechat and Short Message Service on the Quality of Bowel Preparation Unknown status NCT02832869 Phase 4
7 Influence of Synacthen Infusion on the Results of Adrenal Venous Sampling in Patient With Primary Aldosteronism Unknown status NCT02127840 Phase 4 Synacthen infusion during adrenal venous sampling
8 Assessment of the Participation Rate and the Diagnostic Accuracy of a Colorectal Cancer Screening Program: CT Colonography Versus Flexible Sigmoidoscopy. Evaluation of a New Model Based on Telediagnosis Unknown status NCT01739608 Phase 4
9 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
10 Efficacy of an Ecabet Sodium and Proton Pump Inhibitor (PPI) Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection: A Prospective Randomized Controlled Trial Unknown status NCT01308177 Phase 4 Ecabet
11 Efficacy and Safety of Pasireotide Long Acting Release (LAR) in Combination With Weekly Pegvisomant in Previously Controlled Acromegaly Patients on Combination Treatment of Long-Acting Somatostatin Analogues and Weekly Pegvisomant Unknown status NCT02668172 Phase 4 Pasireotide LAR 60 mg;Pegvisomant
12 Prophylactic Pancreatic Duct Stent Placement After Endoscopic Snare Papillectomy of Duodenal Major Papillary Tumors; Prospective, Randomized, Controlled Study Unknown status NCT01737463 Phase 4
13 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
14 Efficacy of Prucalopride Plus Polyethylene Glycol in Bowel Preparation for Colonoscopy Unknown status NCT02781493 Phase 4 2 mg Prucalopride plus 2 L Polyethylene Glycol regimen;2 mg Placebo plus 2 L Polyethylene Glycol regimen
15 The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism Unknown status NCT00451672 Phase 4 bromocriptine
16 Helicobacter Pylori Eradication Rates of Concomitant Therapy and Tailored Therapy Based on 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance: A Multicenter Prospective Randomized Study Unknown status NCT03130452 Phase 4 Lansoprazole 30mg;Amoxicillin 1.0g Tab;Clarithromycin 500mg;Metronidazole 500 mg
17 Optimal Bowel Preparation Regimen for Patients With With a History of Colorectal Resection Before Colonoscopy Unknown status NCT02761317 Phase 4 standard preparation (2L PEG-ELS);low-volume preparation (10 mg bisacodyl plus 2L PEG-ELS);high-volume preparation (4L PEG-ELS)
18 Clinical Effectiveness of Serum Chromogranin A (CgA) Levels on Diagnostic Relevance, Response After Surgical Resection and Recurrence of Pancreatic Endocrine Tumors (PET) Unknown status NCT02759718 Phase 4
19 Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLightTM Laser Photoselective Vaporization of the Prostate (PVP): A Randomized Double Blind Sexual and Urodynamic Assessment Unknown status NCT02749604 Phase 4
20 Does Surgical Debulking Of Pituitary Adenomas Improve Responsiveness To Octreotide LAR In The Treatment Of Acromegaly: An Investigator-Initiated Study Completed NCT01371643 Phase 4 Octreotide LAR
21 Comparative Efficacy of Water & Indigo Carmine vs Water or Air Method Completed NCT01607255 Phase 4 Indigo carmine
22 Preoperative Octreotide Treatment of Patients With Growth Hormone Producing Pituitary Adenomas Completed NCT00521300 Phase 4 Octreotide
23 Can Involvement of Endoscopy Nurse Participation Increase Adenoma Detection Rate During Screening Colonoscopy?:A Prospective Multicenter Randomized Trial Completed NCT01124266 Phase 4
24 A SINGLE-ARM OPEN-LABEL INTERNATIONAL MULTI-CENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB MALATE (SU011248, SUTENT (REGISTERED)) IN PATIENTS WITH PROGRESSIVE ADVANCED METASTATIC WELL-DIFFERENTIATED UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMORS Completed NCT01525550 Phase 4 sunitinib
25 The Effect Of Adding High Dose Simethicone To A Standard Polyethylene Glycol Preparation On Adenoma Detection Rate During Screening Colonoscopy: A Randomized Controlled Pilot Trial Completed NCT03119168 Phase 4 Simethicone Solution
26 A Multi-centre, Randomised, Investigator-blinded Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate) Completed NCT01689792 Phase 4 MOVIPREP;CitraFleet
27 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
28 A Multicenter, Single Arm, Proof of Concept Study to Investigate the Efficacy of an 8 Month Combination Therapy of Octreotide and Cabergoline in Acromegalic Patients Only Partially Responsive to Somatostatin Analog Monotherapy Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
29 Effect of Gum Chewing on Bowel Cleansing Before Colonoscopy: A Prospective Randomized Study Completed NCT02507037 Phase 4 polyethylene glycol
30 Role of Glucagon in Outpatient Colonoscopy? A Prospective Double-Blind Randomized Controlled Trial Completed NCT02078726 Phase 4 Glucagon;Placebo
31 Green Light Laser (XPS) Photoselective Vaporization of the Prostate (PVP) Versus Bipolar Transurethral Vaporization (B.TUVP) of the Prostate for Treatment of Small to Moderate Sized Benign Prostate Hyperplasia: A Randomized Study Completed NCT02283684 Phase 4
32 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment: Correlation With Disease Activity, Insulin Sensitivity and Secretion Parameters Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
33 A Prospective Randomised Controlled Trial Comparing Cap-Assisted Colonoscopy Versus Standard Colonoscopy Completed NCT00930462 Phase 4
34 Evaluation of the Effects of Monopolar Transurethral Resection Versus Bipolar Transurethral Resection and Holmium Laser Enucleation of the Prostate on Urinary and Sexual Function; a Prospective Comparative Study. Completed NCT01810068 Phase 4
35 Efficacy of a Calcimimetic (Cinacalcet) in the Long Term Control of Patients With Primary Hyperparathyroidism Completed NCT02417389 Phase 4 cinacalcet;Alendronate
36 Tailored Bowel Preparation According to Bristol Stool Form Scale: a Prospective, Randomized, Controlled, Investigator-blinded, Multicenter Study Completed NCT02415569 Phase 4 Standard Bowel Prep (2L PEG-ELP);2L PEG-ELP and 10mg bisacodyl;Standard Bowel Prep (2L PEG-ELP)
37 Randomized Study Comparing Holmium Laser Enucleation of the Prostate (HOLEP) Versus Greenlight (XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP) in the Management of Infravesical Obstruction Secondary to BPH Completed NCT01494337 Phase 4
38 Effects of Preoperative Administration of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection(EMR): Prospective, Randomized, Placebo-controlled, Comparative Study Completed NCT00844675 Phase 4 rabeprazole;placebo
39 A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
40 A Randomized, Double-blind, Comparative, Effectiveness and Safety Study of Eleview vs. Hetastarch in Subjects Undergoing Endoscopic Mucosal Resection (EMR) of Colonic Lesions Equal to or Larger Than 11mm Completed NCT03350217 Phase 4 Eleview;Hetastarch
41 EFFICACY EVALUATION OF PRUNUS DOMESTICA EXTRACT ON BENIGN PROSTATE HYPERPLASIA (BPH): An Add on Study Completed NCT02702947 Phase 4
42 A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Impact of Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
43 Long-term (up to 3 Years) Clinical and Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues: Open-labeled, Prospective, Parallel Group Study Recruiting NCT02427295 Phase 4 Sandostatin (Octreotide Acetate)
44 An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment Recruiting NCT01794793 Phase 4 Pasireotide;Cabergoline;Pasireotide
45 Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery Recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
46 Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens Recruiting NCT03298945 Phase 4 Miralax-Gatorade Prep;Golytely
47 The Role of Aldosterone on Sympathetic Nerve Activity and Insulin Sensitivity Recruiting NCT02102243 Phase 4 DEFINITY® infusion;Human Recombinant Regular Insulin infusion;Dextrose infusion
48 Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding Active, not recruiting NCT02032784 Phase 4 octreotide
49 Phase IV, Open-label, Multi-center, Single-arm Study of the Safety and Efficacy of Everolimus (Afinitor) in Adult Patients With Local Advanced or Metastatic, Well Differentiated Progressive Pancreatic Neuroendocrine Tumors (pNET) in China. Active, not recruiting NCT02842749 Phase 4 everolimus
50 A Multicentre Randomized Parallel Group Phase IV Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of PLENVU® Versus SELG-ESSE® Using a 2-Day Split Dosing Regimen. Active, not recruiting NCT03742232 Phase 4 PEG3350;Macrogol 4000

Search NIH Clinical Center for Adenoma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Octreotide
Octreotide Acetate

Genetic Tests for Adenoma

Anatomical Context for Adenoma

MalaCards organs/tissues related to Adenoma:

41
Pituitary, Thyroid, Colon, Prostate, Salivary Gland, Liver, Testes

Publications for Adenoma

Articles related to Adenoma:

(show top 50) (show all 52835)
# Title Authors PMID Year
1
Differentiation of tubular and villous adenomas based on Wnt pathway-related gene expression profiles. 9 38
20514431 2010
2
Biallelic MYH germline mutations as cause of Muir-Torre syndrome. 9 38
19998059 2010
3
Immunohistochemical detection of somatostatin receptor subtype 5 (SSTR-5) in cushing adenoma. 9 38
19894022 2010
4
The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. 9 38
20335450 2010
5
Fish fatty acids alter markers of apoptosis in colorectal adenoma and adenocarcinoma cell lines but fish consumption has no impact on apoptosis-induction ex vivo. 9 38
20107900 2010
6
AMACR is associated with advanced pathologic risk factors in sporadic colorectal adenomas. 9 38
20503447 2010
7
Adrenocortical zonation in humans under normal and pathological conditions. 9 38
20200334 2010
8
Oncogenic KRAS is not necessary for Wnt signalling activation in APC-associated FAP adenomas. 9 38
20196079 2010
9
KRAS mutations in traditional serrated adenomas from Korea herald an aggressive phenotype. 9 38
20305537 2010
10
ACB-PCR quantification of K-RAS codon 12 GAT and GTT mutant fraction in colon tumor and non-tumor tissue. 9 38
20307197 2010
11
Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention. 9 38
20427397 2010
12
Effects of calcium and vitamin D on MLH1 and MSH2 expression in rectal mucosa of sporadic colorectal adenoma patients. 9 38
20332274 2010
13
REG IV overexpression in an early stage of colorectal carcinogenesis: an immunohistochemical study. 9 38
20183800 2010
14
Clear cell adenocarcinoma of the bladder and urethra: cases diffusely mimicking nephrogenic adenoma. 9 38
20060152 2010
15
Chemoprophylaxis in gastrointestinal tumors. 9 38
20496537 2010
16
High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. 9 38
20145615 2010
17
Beta-catenin activation is not involved in sporadic parathyroid carcinomas and adenomas. 9 38
19755524 2010
18
Pituitary adenomas that show a faint GH-immunoreactivity but lack fibrous body: Pit-1 adenoma with endocrinologically low activity. 9 38
20111911 2010
19
Increased expression of HMGA1 correlates with tumour invasiveness and proliferation in human pituitary adenomas. 9 38
20459557 2010
20
Frequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours. 9 38
20208994 2010
21
Complete deletion of Apc results in severe polyposis in mice. 9 38
20010873 2010
22
Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study. 9 38
20233436 2010
23
Identification of histologically distinct conventional adenomas that arise predominately in patients with sessile serrated adenomas. 9 38
20118768 2010
24
Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. 9 38
19965918 2010
25
Immunohistochemical expression of pituitary tumor transforming gene (PTTG) in pituitary adenomas: a correlative study of tumor subtypes. 9 38
20106827 2010
26
The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. 9 38
20093774 2010
27
O-methylguanine-DNA methyltransferase immunoexpression in a double pituitary adenoma: case report. 9 38
20087113 2010
28
Genetic polymorphisms in vitamin D receptor VDR/RXRA influence the likelihood of colon adenoma recurrence. 9 38
20145122 2010
29
Genetic variation in prostaglandin E2 synthesis and signaling, prostaglandin dehydrogenase, and the risk of colorectal adenoma. 9 38
20086108 2010
30
Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor. 9 38
20087348 2010
31
Expression of gastric pyloric mucin, MUC6, in colorectal serrated polyps. 9 38
19855374 2010
32
HERG1 gene expression as a specific tumor marker in colorectal tissues. 9 38
19577877 2010
33
Molecular genetics of hepatocellular neoplasia. 9 38
20182587 2010
34
Elevation of growth hormone secretagogue receptor type 1a mRNA expression in human growth hormone-secreting pituitary adenoma harboring G protein alpha subunit mutation. 9 38
20150876 2010
35
Immunohistochemistry of COUP-TFI: an adjuvant diagnostic tool for the identification of corticotroph microadenomas. 9 38
19526345 2010
36
ACTH-independent Cushing's syndrome with bilateral micronodular adrenal hyperplasia and ectopic adrenocortical adenoma. 9 38
19915020 2010
37
[Differentiated therapy of liver tumors]. 9 38
20062959 2010
38
Identifying mutations for MYH-associated polyposis. 9 38
20063264 2010
39
Gradual loss of functional gap junction within progression of colorectal cancer -- a shift from membranous CX32 and CX43 expression to cytoplasmic pattern during colorectal carcinogenesis. 9 38
20133984 2010
40
Synaptophysin immunoreactivity in adrenocortical adenomas: a correlation between synaptophysin and CYP17A1 expression. 9 38
19755404 2009
41
Beta-catenin nuclear labeling is a common feature of sessile serrated adenomas and correlates with early neoplastic progression after BRAF activation. 9 38
19745699 2009
42
A case of Peutz-Jeghers syndrome with breast cancer, bilateral sex cord tumor with annular tubules, and adenoma malignum caused by STK11 gene mutation. 9 38
19955943 2009
43
Differential effects of reactive nitrogen species on DNA base excision repair initiated by the alkyladenine DNA glycosylase. 9 38
19864471 2009
44
An immunohistochemical study of colon adenomas and carcinomas: E-cadherin, Syndecan-1, Ets-1. 9 38
19253033 2009
45
Clear cell change in colonic polyps. 9 38
18611940 2009
46
Cyclooxygenase-2 expression is related to the epithelial-to-mesenchymal transition in human colon cancers. 9 38
20046424 2009
47
Dissociation of EphB2 signaling pathways mediating progenitor cell proliferation and tumor suppression. 9 38
19914164 2009
48
Polyamines as mediators of APC-dependent intestinal carcinogenesis and cancer chemoprevention. 9 38
20095973 2009
49
Genetic pathways to colorectal cancer. 9 38
19576232 2009
50
Molecular genetics of parathyroid disease. 9 38
19373510 2009

Variations for Adenoma

Expression for Adenoma

Search GEO for disease gene expression data for Adenoma.

Pathways for Adenoma

Pathways related to Adenoma according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.14 TSHR TGFBR2 SMAD4 RET MEN1 LHCGR
2
Show member pathways
12.92 PRL KRAS GNAS CTNNB1 CCND1 APC
3
Show member pathways
12.66 TGFBR2 SMAD4 RET MSH2 MLH1 KRAS
4
Show member pathways
12.64 TGFBR2 SMAD4 MLH1 KRAS CTNNB1 CCND1
5
Show member pathways
12.42 SMAD4 CTNNB1 CDC73 CCND1 APC
6
Show member pathways
12.41 PRL LHCGR KRAS CCND1
7 12.38 TGFBR2 SMAD4 RET MSH2 MLH1 KRAS
8
Show member pathways
12.37 TGFBR2 SMAD4 GNAS CTNNB1 APC
9 12.35 GNAS CTNNB1 CCND1 APC
10 12.29 SMAD4 MEN1 CCND1 APC
11 12.22 TGFBR2 SMAD4 KRAS CTNNB1 CCND1 APC
12 12.17 SMAD4 CTNNB1 CDC73 APC
13 12.04 TGFBR2 SMAD4 CTNNB1 CCND1 APC
14 12 SMAD4 KRAS CTNNB1 APC
15
Show member pathways
11.99 TGFBR2 SMAD4 KRAS CCND1
16 11.99 TGFBR2 SMAD4 MSH2 KRAS CTNNB1 CCND1
17 11.86 KRAS CTNNB1 CCND1 APC
18 11.83 SMAD4 KRAS CTNNB1 CCND1 APC
19 11.81 TGFBR2 SMAD4 KRAS
20 11.8 TGFBR2 SMAD4 KRAS CCND1
21 11.77 SMAD4 CTNNB1 CCND1
22 11.71 CTNNB1 CCND1 APC
23 11.65 TGFBR2 SMAD4 CTNNB1
24 11.56 TGFBR2 SMAD4 CTNNB1
25 11.5 CTNNB1 CCND1 APC
26